Selected research
Industry Research
Postmenopausal Osteoporosis Drugs Industry Research Report 2026
Market perspective
The global Postmenopausal Osteoporosis Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Postmenopausal Osteoporosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Postmenopausal Osteoporosis Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Postmenopausal Osteoporosis Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Postmenopausal Osteoporosis Drugs include Allergan, Amgen Astellas Biopharm, Deltanoid Pharmaceuticals, Noven, Novo Nordisk, Osteologix, PhytoHealth, Radius Health and Tarsa Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Postmenopausal Osteoporosis Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Postmenopausal Osteoporosis Drugs Market by Company
Allergan
Amgen Astellas Biopharm
Deltanoid Pharmaceuticals
Noven
Novo Nordisk
Osteologix
PhytoHealth
Radius Health
Tarsa Therapeutics
Amgen
Pfizer
Eli Lilly
Merck
Novartis
Postmenopausal Osteoporosis Drugs Segment by Type
Antiresorptive Medications
Anabolic Medications
Postmenopausal Osteoporosis Drugs Segment by Application
Hospital
Pharmacy
Other
Postmenopausal Osteoporosis Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Postmenopausal Osteoporosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Postmenopausal Osteoporosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Postmenopausal Osteoporosis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Postmenopausal Osteoporosis Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Postmenopausal Osteoporosis Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Postmenopausal Osteoporosis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Antiresorptive Medications
- Anabolic Medications
Applications
- Hospital
- Pharmacy
- Other
Companies covered
- Allergan
- Amgen Astellas Biopharm
- Deltanoid Pharmaceuticals
- Noven
- Novo Nordisk
- Osteologix
- PhytoHealth
- Radius Health
- Tarsa Therapeutics
- Amgen
- Pfizer
- Eli Lilly
- Merck
- Novartis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Postmenopausal Osteoporosis Drugs Market Size (2021-2032)
- 2.2.2 Global Postmenopausal Osteoporosis Drugs Sales (2021-2032)
- 2.2.3 Global Postmenopausal Osteoporosis Drugs Market Average Price (2021-2032)
- 2.3 Postmenopausal Osteoporosis Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Antiresorptive Medications
- 2.3.3 Anabolic Medications
- 2.4 Postmenopausal Osteoporosis Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Pharmacy
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Postmenopausal Osteoporosis Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Postmenopausal Osteoporosis Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Postmenopausal Osteoporosis Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Postmenopausal Osteoporosis Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Postmenopausal Osteoporosis Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Postmenopausal Osteoporosis Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Postmenopausal Osteoporosis Drugs, Product Type & Application
- 3.8 Global Manufacturers of Postmenopausal Osteoporosis Drugs, Established Date
- 3.9 Global Postmenopausal Osteoporosis Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Allergan
- 4.1.1 Allergan Company Information
- 4.1.2 Allergan Business Overview
- 4.1.3 Allergan Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Allergan Postmenopausal Osteoporosis Drugs Product Portfolio
- 4.1.5 Allergan Recent Developments
- 4.2 Amgen Astellas Biopharm
- 4.2.1 Amgen Astellas Biopharm Company Information
- 4.2.2 Amgen Astellas Biopharm Business Overview
- 4.2.3 Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Product Portfolio
- 4.2.5 Amgen Astellas Biopharm Recent Developments
- 4.3 Deltanoid Pharmaceuticals
- 4.3.1 Deltanoid Pharmaceuticals Company Information
- 4.3.2 Deltanoid Pharmaceuticals Business Overview
- 4.3.3 Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Product Portfolio
- 4.3.5 Deltanoid Pharmaceuticals Recent Developments
- 4.4 Noven
- 4.4.1 Noven Company Information
- 4.4.2 Noven Business Overview
- 4.4.3 Noven Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Noven Postmenopausal Osteoporosis Drugs Product Portfolio
- 4.4.5 Noven Recent Developments
- 4.5 Novo Nordisk
- 4.5.1 Novo Nordisk Company Information
- 4.5.2 Novo Nordisk Business Overview
- 4.5.3 Novo Nordisk Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novo Nordisk Postmenopausal Osteoporosis Drugs Product Portfolio
- 4.5.5 Novo Nordisk Recent Developments
- 4.6 Osteologix
- 4.6.1 Osteologix Company Information
- 4.6.2 Osteologix Business Overview
- 4.6.3 Osteologix Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Osteologix Postmenopausal Osteoporosis Drugs Product Portfolio
- 4.6.5 Osteologix Recent Developments
- 4.7 PhytoHealth
- 4.7.1 PhytoHealth Company Information
- 4.7.2 PhytoHealth Business Overview
- 4.7.3 PhytoHealth Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 PhytoHealth Postmenopausal Osteoporosis Drugs Product Portfolio
- 4.7.5 PhytoHealth Recent Developments
- 4.8 Radius Health
- 4.8.1 Radius Health Company Information
- 4.8.2 Radius Health Business Overview
- 4.8.3 Radius Health Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Radius Health Postmenopausal Osteoporosis Drugs Product Portfolio
- 4.8.5 Radius Health Recent Developments
- 4.9 Tarsa Therapeutics
- 4.9.1 Tarsa Therapeutics Company Information
- 4.9.2 Tarsa Therapeutics Business Overview
- 4.9.3 Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Product Portfolio
- 4.9.5 Tarsa Therapeutics Recent Developments
- 4.10 Amgen
- 4.10.1 Amgen Company Information
- 4.10.2 Amgen Business Overview
- 4.10.3 Amgen Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Amgen Postmenopausal Osteoporosis Drugs Product Portfolio
- 4.10.5 Amgen Recent Developments
- 4.11 Pfizer
- 4.11.1 Pfizer Company Information
- 4.11.2 Pfizer Business Overview
- 4.11.3 Pfizer Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Pfizer Postmenopausal Osteoporosis Drugs Product Portfolio
- 4.11.5 Pfizer Recent Developments
- 4.12 Eli Lilly
- 4.12.1 Eli Lilly Company Information
- 4.12.2 Eli Lilly Business Overview
- 4.12.3 Eli Lilly Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Eli Lilly Postmenopausal Osteoporosis Drugs Product Portfolio
- 4.12.5 Eli Lilly Recent Developments
- 4.13 Merck
- 4.13.1 Merck Company Information
- 4.13.2 Merck Business Overview
- 4.13.3 Merck Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Merck Postmenopausal Osteoporosis Drugs Product Portfolio
- 4.13.5 Merck Recent Developments
- 4.14 Novartis
- 4.14.1 Novartis Company Information
- 4.14.2 Novartis Business Overview
- 4.14.3 Novartis Postmenopausal Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Novartis Postmenopausal Osteoporosis Drugs Product Portfolio
- 4.14.5 Novartis Recent Developments
5 Global Postmenopausal Osteoporosis Drugs Market Scenario by Region
- 5.1 Global Postmenopausal Osteoporosis Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Postmenopausal Osteoporosis Drugs Sales by Region: 2021-2032
- 5.2.1 Global Postmenopausal Osteoporosis Drugs Sales by Region: 2021-2026
- 5.2.2 Global Postmenopausal Osteoporosis Drugs Sales by Region: 2027-2032
- 5.3 Global Postmenopausal Osteoporosis Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Postmenopausal Osteoporosis Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Postmenopausal Osteoporosis Drugs Revenue by Region: 2027-2032
- 5.4 North America Postmenopausal Osteoporosis Drugs Market Facts & Figures by Country
- 5.4.1 North America Postmenopausal Osteoporosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Postmenopausal Osteoporosis Drugs Sales by Country (2021-2032)
- 5.4.3 North America Postmenopausal Osteoporosis Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Postmenopausal Osteoporosis Drugs Market Facts & Figures by Country
- 5.5.1 Europe Postmenopausal Osteoporosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Postmenopausal Osteoporosis Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Postmenopausal Osteoporosis Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Postmenopausal Osteoporosis Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Postmenopausal Osteoporosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Postmenopausal Osteoporosis Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Postmenopausal Osteoporosis Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Postmenopausal Osteoporosis Drugs Market Facts & Figures by Country
- 5.7.1 South America Postmenopausal Osteoporosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Postmenopausal Osteoporosis Drugs Sales by Country (2021-2032)
- 5.7.3 South America Postmenopausal Osteoporosis Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Postmenopausal Osteoporosis Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Postmenopausal Osteoporosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Postmenopausal Osteoporosis Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Postmenopausal Osteoporosis Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Postmenopausal Osteoporosis Drugs Sales by Type (2021-2032)
- 6.1.1 Global Postmenopausal Osteoporosis Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Postmenopausal Osteoporosis Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Postmenopausal Osteoporosis Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Postmenopausal Osteoporosis Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Postmenopausal Osteoporosis Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Postmenopausal Osteoporosis Drugs Sales by Application (2021-2032)
- 7.1.1 Global Postmenopausal Osteoporosis Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Postmenopausal Osteoporosis Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Postmenopausal Osteoporosis Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Postmenopausal Osteoporosis Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Postmenopausal Osteoporosis Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Postmenopausal Osteoporosis Drugs Value Chain Analysis
- 8.1.1 Postmenopausal Osteoporosis Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Postmenopausal Osteoporosis Drugs Production Mode & Process
- 8.2 Postmenopausal Osteoporosis Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Postmenopausal Osteoporosis Drugs Distributors
- 8.2.3 Postmenopausal Osteoporosis Drugs Customers
9 Global Postmenopausal Osteoporosis Drugs Analyzing Market Dynamics
- 9.1 Postmenopausal Osteoporosis Drugs Industry Trends
- 9.2 Postmenopausal Osteoporosis Drugs Industry Drivers
- 9.3 Postmenopausal Osteoporosis Drugs Industry Opportunities and Challenges
- 9.4 Postmenopausal Osteoporosis Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst